eligible

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial show investigational treatment with epcoritamab in combination with…

2 months ago
NuggMD Now Serves All Eligible Medical Cannabis Patients Nationwide via Secure Telehealth PlatformNuggMD Now Serves All Eligible Medical Cannabis Patients Nationwide via Secure Telehealth Platform

NuggMD Now Serves All Eligible Medical Cannabis Patients Nationwide via Secure Telehealth Platform

Los Angeles, June 10, 2025 (GLOBE NEWSWIRE) -- NuggMD, the nation’s leading medical marijuana telehealth platform, is proud to announce…

2 months ago